379 results about "Glidant" patented technology

A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxo-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilised by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a stable solid pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. More precisely, the present invention relates to the new stable solid pharmaceutical formulation containing as an active ingredient a HMG-CoA reductase inhibitor, such as atorvastatin, pravastatin, fluvastatin and cerivastatin or pharmaceutically acceptable salts thereof.

The invention relates to a preparation method for metformin hydrochloride sustained-release tablets. The preparation method comprises the following steps: firstly, dissolving ethyl cellulose into ethanol solution, blending the ethyl cellulose with metformin hydrochloride to produce granules, and drying and sieving the granules at 45 to 55 DEG C; secondly, dissolving hydroxypropyl methylcellulose into ethanol solution to produce bonding agent, blending the granules prepared in step one, hydroxypropyl methylcellulose, ethyl cellulose and pore forming agent, adding the bonding agent, performing sieving and granulation, adding hydroxypropyl methylcellulose and lubricant, evenly blending, detecting the content, determining the tablet weight, and pressing into plain tablets; thirdly, dissolving film forming agent, plasticizer, masking agent and glidant for hydroxypropyl methylcellulose and ethyl cellulose into ethanol solution, completely stirring for more than 1 hour to produce sustained-release preparation coating solution, and finally obtaining the metformin hydrochloride sustained-release tablets by performing film coating to the plain tablets. The sustained-release preparation not only embodies the main characteristics of the sustained-release preparation for continuous sustained release of drug, but also presents high bioavailability.

A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

Apparatus, process and article for treating an aqueous solution containing a chemical contaminant. The process includes contacting an aqueous solution containing a chemical contaminant with an aggregate composition comprising an insoluble rare earth-containing compound to form a solution depleted of chemical contaminants. The insoluble rare earth-containing compound can include one or more of cerium, lanthanum, or praseodymium. A suitable insoluble cerium-containing compound can be derived from a cerium carbonate, cerium oxalate and / or a cerium salt. The aggregate composition can include more than 10.01% by weight of the insoluble rare earth-containing compound, and in a particular embodiment consists essentially of one or more cerium oxides, and optionally a binder and / or flow aid. Although intended for a variety of fluid treatment applications, such applications specifically include removing or detoxifying chemical contaminants in water.

The invention relates to a pharmaceutical composition containing mosapride citrate which is applicable to the usage of direct powder compression for preparation and a preparation method thereof. The pharmaceutical composition further contains a disintegrant, a thinner, a lubricant, a glidant and an adhesive in addition to the active component of the mosapride citrate. The pharmaceutical composition is applicable to the preparation of dispersible tablets which can be fully disintegrated in 2 minutes in water under the temperature of 19 DEG C to 21 DEG C and pass through a No. 2 screen, the hardness is 8 to 11Kg, and the dissolution rate is in line with the relevant provisions, thus solving the problems of higher relevant substances, instable quality and difficult packaging of the mosapridecitrate dispersible tablets prepared by wet granulation.

An ebastine solid oral preparation and preparation method are disclosed in the present invention. Made of ebastine, ethanol solution, cosolvent, diluent or filler, disintegrating agent, taste correcting agent, glidants or dispersing agent, effervescing agent, lubricant in proportion, its step is that firstly adding ebastine into ethanol solution, and then adding cosolvent organic acid, leading it to dissolve entirely; secondly mixing the diluent or filler, disintegrating agent, taste correcting agent, effervescing agent with dispersing agent, to obtain a mixer; third mixing the front two, preparing soft material, preparing granules, then adding disintegrating agent, effervescing agent, taste correcting agent, glidants and lubricant, tabletting or filling capsules, packing to obtain a solid oral preparation. The present invention preparing oral disintegrable tablet, dispersing tablet have short disintegrating time, good dispersing state. The obtained oral disintegrable tablet, dispersing tablet and chewing tablet have good taste and mouth feel, the obtained solid oral preparations dissolving out are all rapid. The method is easy, simple operation, without needing special equipment, and lower production cost.

The present invention relates to lightweight components in hybrid construction, also referred to as hybrid components or hollow-chamber lightweight components, comprising a base body which is made by aluminum of which the surface is preprocessed and is reinforced by means of thermoplastics and is suitable for the transmission of high mechanical loads, wherein, the thermoplastics is added with a special glidant for improving physical property.

The invention belongs to the pharmaceutical field and relates to a preparation method of a low melting point drug solid dispersion. The preparation method comprises the following steps: crushing pharmaceutical raw materials and auxiliary materials, passing through a 60-120-mesh sieve, then uniformly mixing, sealing, placing at the constant temperature of 45-140 DEG C for 0.5-4h, cooling to room temperature and obtaining the solid dispersion, wherein the pharmaceutical raw materials are insoluble drugs with the melting points in the range of 45-130 DEG C; and the auxiliary materials comprise a filling agent, a disintegrant, a dry adhesive, a lubricating agent, a glidant and a surfactant. The preparation method has the following advantages: simple operation, low equipment requirements and no solvent residue; the prepared solid dispersion is easy to crush and can be prepared into quick-release tablets, capsules, power or slow-release tablets; a quick-release preparation prepared through the preparation method has high drug loading, fast drug dissolution speed and high dissolution rate; and the prepared slow-release tablets have good uniformity and stable drug release.

The present invention relates to lightweight components of hybrid design, also termed hybrid component or hollow-chamber lightweight component, composed of a parent body which is composed of surface-pretreated aluminium and which is reinforced by means of thermoplastics and is suitable for the transmission of high mechanical loads, where particular flow aids are added to the thermoplastic in order to improve its physical properties.

The invention discloses brass flux-cored brazing filler metal with reducing agents and flow aids. The brass flux-cored brazing filler metal comprises a brazing filler metal pipe with a spiral lap seam, the brazing filler metal pipe is formed by rotatably rolling strip-shaped brass base brazing filler metal, and a welding wire and a flux core prepared from brass brazing flux, the reducing agents and the flow aids are wrapped by the brazing filler metal pipe. In the preparation process, the brass base brazing filler metal is molten according to a conventional method for ingot casting and is processed into strip-shaped brazing filler metal, then the brazing filler metal is rotatably rolled to the brazing filler metal pipe with the spiral lap seam, and in the rolling process, the welding wire and the flux core are added into the brazing filler metal pipe. A brass flux-cored brazing filler metal wire or bar or brazing filler metal ring are manufactured through rolling or drawing. The brass flux-cored brazing filler metal has the advantages that Sn, Ni, Si and other elements are added into the brazing filler metal in the form of the welding wire, when the content of alloy elements in the brass brazing filler metal is low, the excellent processing performance can still be kept, the brazing filler metal can achieve good wettability and fluidity, meanwhile, weld strength, low-temperature impact toughness and the anti-cracking ability are improved, and ductile-brittle transition temperature is lowered.